Dexamethasone Sodium Phosphate
[1 vial $6.20]
- IV, PO
- cerebral oedema
- upper airway oedema
- nausea and vomiting
- other inflammatory conditions
PRESENTATION AND ADMINISTRATION:
4mg/1ml ampoule and 8mg/2ml vial
Inject undiluted over 3-5 minutes
Compatible with the following IV fluids:
0.9% Sodium chloride, glucose and sodium chloride, 5% dextrose
Store at room temperature.
Protect from light and freezing.
1mg and 4mg tablets (white)
8-16mg stat, then 4-8mg 4 hourly reducing over 3-5 days to 2mg 8 to 12 hourly Nausea: 4-8mg IV stat
Adult airway oedema:
8-16mg 1hr pre extubation (may be repeated 8 hourly)
DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY: Dose as in normal renal function
DOSAGE IN PAEDIATRICS:
- IV / PO:
0.25-1mg/kg stat then 0.1-0.2mg/kg 4 hourly reducing over 3-5 days to 0.05mg/kg 8-12 hourly Severe croup or extubation stridor: 0.6mg/kg stat IV, then 1mg/kg prednisilone 8-12 hourly
- Dexamethasone is a glucorticoid which is 25 times more potent than hydrocortisone with respect to its glucocorticoid activity; it has no mineralocorticoid effect. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, including dexamethasone, are primarily used for their potent anti- inflammatory effects in disorders of many organ systems.
- Systemic fungal infections
- Hypersensitivity to dexamethasone or any component of the product
Anaphylactoid and hypersensitivity reactions have been reported for dexamethasone sodium phosphate injection Dexamethasone sodium phosphate injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
- Exacerbation of fungal infections:
Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections unless they are needed to control drug reactions due to amphotericin B.
- Relative steroid deficiency:
In patients on corticosteroid therapy subjected to any unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Drug-induced secondary adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.
- Masking of signs of infection:
Corticosteroids may mask some signs of infection, and new infections may appear during their use.
Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.
- Laboratory Tests:
No tests in addition to routine ICU tests are indicated
Drug/Laboratory Test Interactions:
IMPORTANT DRUG INTERACTIONS FOR THE ICU
- Phenytoin, phenobarbital, ephedrine, and rifampin may enhance the metabolic clearance of corticosteroids resulting in decreased blood levels and lessened physiologic activity, thus requiring adjustment in corticosteroid dosage.
- Fluid and electrolyte disturbances:
Sodium retention; fluid retention; congestive heart failure in susceptible patients; potassium loss; hypokalemic alkalosis; hypertension. Musculoskeletal: Muscle weakness; steroid myopathy; loss of muscle mass; osteoporosis; vertebral compression fractures; aseptic necrosis of femoral and humeral heads; pathologic fracture of long bones; tendon rupture.
Peptic ulcer with possible subsequent perforation and hemorrhage; perforation of the small and large bowel, particularly in patients with inflammatory bowel disease; pancreatitis; abdominal distention; ulcerative esophagitis.
Impaired wound healing; thin fragile skin; petechiae and ecchymoses; erythema; increased sweating; may suppress reactions to skin tests; burning or tingling, especially in the perineal area (after IV injection); other cutaneous reactions, such as allergic dermatitis, urticaria, angioneurotic edema.
Convulsions; increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment; vertigo; headache; psychic disturbances. Endocrine: Menstrual irregularities; development of cushingoid state; suppression of growth in children; secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness; decreased carbohydrate tolerance; manifestations of latent diabetes mellitus; increased requirements for insulin or oral hypoglycemic agents in diabetics; hirsutism.
Negative nitrogen balance due to protein catabolism.
Myocardial rupture following recent myocardial infarction
Anaphylactoid or hypersensitivity reactions; thromboembolism; weight gain; increased appetite; nausea; malaise; hiccups.